FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

HELLUMS RHONDA LYNETTE

2. Date of Event Requiring Statement (MM/DD/YYYY)
2/1/2019 

3. Issuer Name and Ticker or Trading Symbol

ARATANA THERAPEUTICS, INC. [PETX]

(Last)        (First)        (Middle)

C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
CHIEF FINANCIAL OFFICER /

(Street)

LEAWOOD, KS 66211       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   26501   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)     (1) 3/2/2024   Common Stock   25000   $22.91   D    
Stock Option (Right to Buy)     (2) 1/28/2025   Common Stock   2650   $17.18   D    
Stock Option (Right to Buy)     (3) 1/21/2026   Common Stock   6700   $3.14   D    
Stock Option (Right to Buy)     (4) 1/12/2027   Common Stock   4100   $8.02   D    
Stock Option (Right to Buy)     (5) 1/24/2028   Common Stock   14700   $4.83   D    
Stock Option (Right to Buy)     (6) 1/23/2029   Common Stock   15100   $4.22   D    

Explanation of Responses:
(1)  Fully vested as of March 3, 2018.
(2)  Fully vested as of January 29, 2019.
(3)  Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2017 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2020, subject to continued service with the Issuer through the applicable vesting dates.
(4)  Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2018 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2021, subject to continued service with the Issuer through the applicable vesting dates.
(5)  Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2019 and vests as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2022, subject to continued service with the Issuer through the applicable vesting dates.
(6)  Vests as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2020 and as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2023, subject to continued service with the Issuer through the applicable vesting dates.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
HELLUMS RHONDA LYNETTE
C/O ARATANA THERAPEUTICS, INC.
11400 TOMAHAWK CREEK PARKWAY, SUITE 340
LEAWOOD, KS 66211

CHIEF FINANCIAL OFFICER

Signatures
/s/ John C. Ayres as Attorney-in-Fact for Rhonda Lynette Hellums 2/5/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Grafico Azioni ARATANA THERAPEUTICS, INC. (NASDAQ:PETX)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di ARATANA THERAPEUTICS, INC.
Grafico Azioni ARATANA THERAPEUTICS, INC. (NASDAQ:PETX)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di ARATANA THERAPEUTICS, INC.